 Currently, only acute intravenous administration takes place.The effects of amrinone vary widely with species and experimental condition; therefore inotropic effects are variable.A loss in sensitivity to PDE III inhibitors has been observed in end stage heart failure in humans and thus other treatment options may be necessary to improvement in these stages.